Inhalation Sciences AB raises 3.5 MSEK in new share issue ahead of IPO
STOCKHOLM, SWEDEN – May 8, 2017. Inhalation Sciences, a leading labtech company, has raised 3.5 MSEK in a private placement directed at current owners and a consortium of private Investors. The funds will be used to increase sales and development initiatives, moving the company towards its planned listing in Q.3 2017.
The new share issue raised a strong interest and was significantly oversubscribed.
CEO Fredrik Sjövall: “Both current and new investors have shown great interest in, and appreciation of, the development of Inhalation Sciences AB (ISAB). We achieved significant milestones in 2016 and moved closer to our vision of PreciseInhale becoming the standard R&D tool for inhalation research worldwide. 2017 has started positively with many product and service sales discussions ongoing and completed.”
Inhalation Sciences are in the preparation phase for an IPO in Q.3.
CEO Fredrik Sjövall: “Our PreciseInhale system is installed at some of the world’s leading pharmaceuticals and research organizations. Being a listed company will support us in the further expansion of our company and add leverage in our business discussions”
About Inhalation Sciences AB
Inhalation Sciences develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.
For further information, please contact:
Fredrik Sjövall, CEO
+46 (0)70 64 508 75